ICaPath


ICaPath is dedicated to pioneering breakthrough therapies for cancer treatment through its proprietary PLGA nanoparticle platform. The company develops innovative immunotherapy solutions, including systemic immunostimulation and controlled delivery of cytokines like IL-12, to address significant unmet medical needs in oncology. With a focus on personalized medicine, ICaPath combines advanced drug delivery technology with immuno-surveillance systems to improve patient outcomes and meet regulatory pathways, aiming to revolutionize cancer care.

Industries

biopharma
biotechnology
life-science

Nr. of Employees

small (1-50)

ICaPath

Morgantown, West Virginia, United States, North America


Products

PLGA nanoparticle delivery platform

A nanoparticle-based delivery platform using PLGA to encapsulate biologics and enabling controlled, prolonged release and improved pharmacokinetic stability for immunotherapeutics.

Recombinant interleukin-12 therapeutic candidate (PLGA-encapsulated)

A recombinant IL-12 protein candidate formulated for systemic, low-dose administration via PLGA encapsulation to provide sustained immune stimulation while addressing historical toxicity associated with high-dose unencapsulated IL-12.

Immuno-surveillance diagnostic assay (flow cytometry)

A diagnostic workflow for real-time analysis of immune status using fluorescent labeling and multi-parameter flow cytometry panels to quantify leukocyte subsets and activation/exhaustion markers for monitoring patients undergoing immunotherapy.


Services

GMP manufacturing coordination via CDMOs

Coordination and use of contract manufacturing organizations to produce recombinant cytokine and PLGA nanoparticle material under GMP for clinical supply.

Regulatory strategy and pre-IND support

Regulatory planning and engagement support including preparation for and participation in pre-IND discussions with regulatory authorities.

Immuno-surveillance and immune profiling services

Flow cytometry-based immune monitoring including fluorescent labeling, multi-parameter staining, and analysis of leukocyte subsets and activation/exhaustion markers.

IP licensing and commercialization support

Management and licensing of patent-protected delivery technology, and preparation of investor-facing materials to support commercial partnerships.

Expertise Areas

  • Nanoparticle drug delivery
  • Immunotherapy development
  • Immune monitoring and immuno‑surveillance
  • Preclinical development and IND-enabling studies
  • Show More (4)

Key Technologies

  • PLGA nanoparticle encapsulation
  • Controlled-release formulation
  • Recombinant cytokine therapeutics (interleukin-12)
  • Multi-parameter flow cytometry
  • Show More (4)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.